Paradigm Biopharmaceuticals will keep its ASX securities suspended until at least 30 September while it reviews interim Phase 3 data and assesses the operational and financial consequences. The company also remains in discussions with Obsidian Global GP, LLC, but has not disclosed the trial results or their direction.
- Trading suspension extended for PAR and PAROB
- Phase 3 interim analysis remains under review
- Operational and financial implications still being assessed
- Discussions with Obsidian Global continue
- Update expected by 30 September trading
Trading Suspension Extended to 30 September
Paradigm Biopharmaceuticals Limited (ASX:PAR) has asked the ASX to keep its ordinary shares and PAROB securities suspended from quotation, extending a trading halt that was due to be reconsidered on Monday. The company has requested that the suspension remain in place until the commencement of trading on Wednesday, 30 September 2026.
The reason is not a routine timetable adjustment. Paradigm says it needs more time to review interim analysis data from its Phase 3 clinical trial and assess the resulting operational and financial implications for the business. It also says discussions with Obsidian Global GP, LLC remain ongoing.
Phase 3 Results Remain Undisclosed
The filing gives no indication whether the interim analysis is favourable or unfavourable. It does not disclose the data, identify any clinical outcome, or explain what operational or financial consequences the company is assessing. That leaves the central investment question unresolved while trading remains unavailable.
Paradigm says the continuation is intended to prevent trading in an uninformed market. The company anticipates releasing a further announcement by the proposed resumption date, although it has also said it will update the market if that timing changes.
Next Update Carries Clinical and Financial Weight
The next announcement is therefore expected to address more than the Phase 3 readout alone. Shareholders will need to parse how Paradigm describes the interim data, what operational changes may follow, and whether the company’s assessment points to additional financial pressure or a revised path forward. Until then, the suspension itself signals that the material issues identified in the filing have not yet been settled.
Bottom Line?
The key catalyst is now the promised update by 30 September, but its timing may change and the filing offers no clue about the direction of the Phase 3 data.
Questions in the middle?
- What does the interim Phase 3 analysis show, and will it support continued development?
- What operational and financial implications is Paradigm assessing?
- What is the current status and likely outcome of discussions with Obsidian Global?